Cargando…

Decentralized Clinical Trials: The Future of Medical Product Development?∗

[Figure: see text]

Detalles Bibliográficos
Autor principal:	Van Norman, Gail A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Translational Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093545/ https://www.ncbi.nlm.nih.gov/pubmed/33997523 http://dx.doi.org/10.1016/j.jacbts.2021.01.011

Ejemplares similares

Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach?
por: Van Norman, Gail A.
Publicado: (2019)

“Warp Speed” Operations in the COVID-19 Pandemic: Moving Too Quickly?
por: Van Norman, Gail A.
Publicado: (2020)

Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use—Patient Harms and Prescriber Responsibilities
por: Van Norman, Gail A.
Publicado: (2023)

Phase II Trials in Drug Development and Adaptive Trial Design
por: Van Norman, Gail A.
Publicado: (2019)

Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion
por: Goodson, Noah, et al.
Publicado: (2022)

Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials
por: Van Norman, Gail A.
Publicado: (2020)

Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials
por: Van Norman, Gail A.
Publicado: (2021)

Towards a conceptual framework for addressing state-level barriers to decentralized clinical trials in the U.S.
por: Zawada, Stephanie J., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

MicroRNA-Based Diagnostics in Heart Diseases: Current Limitations and Future Perspectives
por: Düsing, Philip, et al.
Publicado: (2021)

Potentiation of Insulin Signaling Contributes to Heart Failure in Type 2 Diabetes: A Hypothesis Supported by Both Mechanistic Studies and Clinical Trials
por: Packer, Milton
Publicado: (2018)

Inherent privacy limitations of decentralized contact tracing apps
por: Bengio, Yoshua, et al.
Publicado: (2021)

Current challenges in metastasis research and future innovation for clinical translation
por: Parker, Amelia L., et al.
Publicado: (2022)

Overcoming Barriers to Development of Novel Therapies for Cardiovascular Disease: Insights From the Oncology Drug Development Experience
por: Khakoo, Aarif Y., et al.
Publicado: (2019)

Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions
por: Ajufo, Ezimamaka, et al.
Publicado: (2023)

Detection and Management of Geographic Disparities in the TOPCAT Trial: Lessons Learned and Derivative Recommendations
por: Bristow, Michael R., et al.
Publicado: (2016)

Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012
por: Hwang, Thomas J., et al.
Publicado: (2016)

A Perspective on the Delivery of Renal Denervation Therapy Based on Pre-Clinical Data
por: Tellez, Armando, et al.
Publicado: (2016)

The Central Dogma Decentralized: New Perspectives on RNA Function and Local Translation in Neurons
por: Holt, Christine E., et al.
Publicado: (2013)

The challenge of developing pain medications for children: therapeutic needs and future perspectives
por: Eerdekens, Mariëlle, et al.
Publicado: (2019)

International Microorganism Day: facilitating global outreach events using a decentralized model
por: Koursari, Eleni, et al.
Publicado: (2023)

Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try”
por: Van Norman, Gail A.
Publicado: (2018)

Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies
por: Van Norman, Gail A.
Publicado: (2018)

Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM’s Law
por: Van Norman, Gail A.
Publicado: (2017)

Expanded Patient Access to Investigational New Devices: Review of Emergency and Nonemergency Expanded Use, Custom, and 3D-Printed Devices
por: Van Norman, Gail A.
Publicado: (2018)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016)

Drugs and Devices: Comparison of European and U.S. Approval Processes
por: Van Norman, Gail A.
Publicado: (2016)

Update to Drugs, Devices, and the FDA: How Recent Legislative Changes Have Impacted Approval of New Therapies
por: Van Norman, Gail A.
Publicado: (2020)

Artificial Intelligence in Medical OSCEs: Reflections and Future Developments
por: Soong, Tse Kiat, et al.
Publicado: (2021)

Technology Transfer: From the Research Bench to Commercialization: Part 2: The Commercialization Process
por: Van Norman, Gail A., et al.
Publicado: (2017)

Technology Transfer: From the Research Bench to Commercialization: Part 1: Intellectual Property Rights—Basics of Patents and Copyrights
por: Van Norman, Gail A., et al.
Publicado: (2017)

Designing resilient decentralized energy systems: The importance of modeling extreme events and long-duration power outages
por: Hanna, Ryan, et al.
Publicado: (2021)

Mobile and pervasive computing technologies and the future of Alzheimer’s clinical trials
por: Doraiswamy, P. Murali, et al.
Publicado: (2018)

Failure to Launch: Targeting Inflammation in Acute Coronary Syndromes
por: Rymer, Jennifer A., et al.
Publicado: (2017)

Ethical and Clinical Considerations During the Coronavirus Era
por: McGee, Maria E., et al.
Publicado: (2021)

Apolipoprotein A-I for Cardiac Recovery Post–Myocardial Infarction
por: Richart, Adele L., et al.
Publicado: (2021)

Variations on fetal heart rate variability
por: Shaw, C. J., et al.
Publicado: (2016)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation: A Report From the National Heart, Lung, and Blood Institute and the National Institutes of Health Office of the Director Workshop
por: Mehra, Reena, et al.
Publicado: (2022)

Application of Internet of Medical/Health Things to Decentralized Clinical Trials: Development Status and Regulatory Considerations
por: Sato, Takahiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_15ausj6iptkk2qs3235c1fl4dp